BI | pharmaphorum

News

Boehringer buys immunotherapy biotech AMAL Therapeutics

Germany’s Boehringer Ingelheim has bought the Swiss biotech AMAL Therapeutics, a privately-held Swiss biotech focused on immunotherapy and vaccines in oncology.

News

Boehringer and Sarah Cannon team for immune-oncology venture

Partnership will seek to develop two immune checkpoint inhibitor candidates.

News

Sobi adds rare lymphoma drug with $580m Innate tie-up

Sobi chief executive Guido Oelkers is preparing his exit, but is still cutting deals, licensing a lymphoma drug from Innate for up to $580m.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

BI

Editor's Picks